Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09TGT
|
|||
| Former ID |
DIB003134
|
|||
| Drug Name |
Atu-027
|
|||
| Synonyms |
PI3K expression inhibitors (AtuPLEX, cancer), Atugen; Phosphoinositide 3 kinase expression inhibitors (AtuPLEX, cancer), Atugen
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Silence Therapeutics AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protein kinase N3 (PKN3) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00938574) Study With Atu027 in Patients With Advanced Solid Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Company report (Silence Therapeutics) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.